The preliminary results of one trial indicate that the inclusion of OP-1250 alongside ribociclib and alpelisib has been well clinically tolerated, demonstrating a manageable safety profile, potent anti-tumor efficacy, and sustained benefits, with 41% of patients observing a tumor size decrease in advanced and/or metastatic ER+/HER2-BC [98]. Here, ERBB2 is linked to neoplasm.